Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion

PHASE4CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Adenine Phosphoribosyltransferase Deficiency
Interventions
DRUG

Allopurinol

This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.

DRUG

Febuxostat

This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.

Trial Locations (1)

101

Landspitali - The National University Hospital of Iceland, Reykjavik

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mayo Clinic

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Landspitali University Hospital

OTHER